Yahoo Web Search

  1. Roche RHHBY announced positive data on the immuno-oncology drug, Tecentriq (atezolizumab), from a late-stage study in patients with advanced non-small cell lung cancer (NSCLC). The phase III ...

  2. So far this year, GlaxoSmithKline plc’s GSK shares have outperformed the industry. Trelegy Ellipta, which provides three medicines in a single inhaler to treat COPD and Juluca (dolutegravir ...

  3. Bristol-Myers Squibb Company BMY announced long-term pooled efficacy and safety results from the phase III CheckMate-017 and CheckMate-057 studies in patients with previously-treated, advanced ...

  4. Neurotrope shares crash after Alzheimer's drug fails in trial

    Reuters via Yahoo FinanceSep 09 13:20 PM

    Several drugmakers such as Eli Lilly, AstraZeneca Plc, Roche AG, Pfizer Inc, Merck and Co Inc and Johnson and Johnson have all previously failed in their attempts ...

  5. X Genomics Inc (NASDAQ: TXG) (listed its shares on Nasdaq on Sept. AxsomeTherapeutics Inc (NASDAQ: AXSM) Bioanalytical Systems, Inc. NASDAQ: BASI) BioCardia Inc ( ...

  6. The settlement could be valued at up to $12 billion, they said, which would make it the largest such settlement in U.S. pharmaceutical history. * Merck & Co $4.85 billion, 2007 ...

  7. MOVES-Credit Suisse bolsters life sciences banking team -memo

    Reuters via Yahoo FinanceSep 05 22:10 PM

    Credit Suisse Group AG has brought on three new senior investment bankers as it continues to build out its healthcare investment banking division, according to an internal memo reviewed by Reuters ...

  8. Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders ...

  9. Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial testing it in patients with a type of tumor that ...

  10. Potential approval of the vaccine will trigger issuance of a priority review voucher owned by Merck and in which NewLink has a substantial economic interest. The priority review voucher ...

  1. Ads
    related to MERCK & CO., INC